The Medicines and Healthcare products Regulatory Agency said AstraZeneca’s GLP-1 drug for type 2 diabetes, called exenatide and marketed as Bydureon, was also included in the review.

The drug, efruxifermin, also met secondary efficacy goals when tested alongside a diabetes treatment belonging to a class of drugs known as GLP-1 receptor agonists in the trial.